Prelude Therapeutics (PRLD) EBITDA (2019 - 2026)

Prelude Therapeutics has disclosed EBITDA across 8 years of filings, most recently posting -$10.4 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$10.4 million, up 67.5% year-over-year; the trailing twelve-month figure through Mar 2026 was -$77.9 million (up 38.98% YoY), and the FY2025 annual result was -$99.5 million, up 21.86% from the prior year.
• EBITDA came in at -$10.4 million for Q1 2026 at Prelude Therapeutics, up from -$16.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$10.4 million in Q1 2026 to a low of -$34.8 million in Q2 2024.
• The 5-year median for EBITDA is -$30.5 million (2023), against an average of -$27.9 million.
• Across the five-year window, EBITDA slumped 45.85% in 2022 and jumped 67.5% in 2026, its largest moves.
• Prelude Therapeutics' EBITDA stood at -$28.0 million in 2022, then declined by 15.29% to -$32.2 million in 2023, then gained by 10.49% to -$28.9 million in 2024, then soared by 43.0% to -$16.5 million in 2025, then surged by 36.58% to -$10.4 million in 2026.
• The last three EBITDA figures came in at -$10.4 million (Q1 2026), -$16.5 million (Q4 2025), and -$19.7 million (Q3 2025), per Business Quant data.